China Pharma Pure Powder manufacturer

Antibacterial Agent Marbofloxacin For Cats Veterinary Drug 115550-35-1

Product Details:
Place of Origin: Xi'An,China
Brand Name: wango
Certification: USP, BP
Model Number: WG-0015
Payment & Shipping Terms:
Minimum Order Quantity: 1kilogram every time
Price: FOB price 620-650usd/kg ,can be Negotiable .
Packaging Details: 10-1000 gram Aluminum Foil Bag Packaging by TNT or DHL , 25kilogram per drum .
Delivery Time: 3-5 working days
Payment Terms: L/C, T/T, Western Union, MoneyGram
Supply Ability: 1000kilogram every month

Detail Information

Usage: Veterinary Colour: Yellow Fine Powder
Function: Veterinary Drug Cas: 115550-35-1
High Light:

Antibacterial Agent Marbofloxacin For Cats

,

Veterinary Marbofloxacin For Cats

,

115550-35-1 Drug

Product Description

Marbofloxacin Treating Dogs And Cats And For Urinary Tract Infections veterinary Medicine Cas 115550-35-1 2000kg fresh stock of the 2021 year

 

 

 

 

 

Name of Product:

Marbofloxacin

Shelf Life:

5 years

Specification:

EP8

Test Items

Specification

Results of Analysis

Appearance

Light yellow crystalline powder

Conforms

Solubility

Slightly soluble in water, sparingly soluble or slightly soluble in methylene chloride, very slightly soluble in ethanol (96 percent)

Conforms

Identification

Conforms to the marbofloxacin CRS

Conforms

Absorbance

≤0.20

0.08

Loss on drying

≤0.5%

0.12%

Sulphated ash

≤0.1%

0.05%

Heavy metals

≤20ppm

<20ppm

Related substance (HPLC)

Impurity A≤0.1%

Not detected

Impurity B≤0.1%

Not detected

Impurity C≤0.2%

0.06%

Impurity D≤0.2%

Not detected

Impurity E≤0.2%

Not detected

Any other single impurity≤0.2%

Not detected

Total impurities≤0.5%

0.06%

Residual solvents

ethanol≤5000ppm

309ppm

toluene≤890ppm

457ppm

methylene chloride≤600ppm

Not detected

Assay

99.0% to 101.0% (dried substance)

100%

 

 

Fluoroquinolones are used for the treatment of deep and superficial skin infections, urinary tract infections in dogs, skin and soft tissue infections in cats, acute upper respiratory tract infections.

Used for respiratory tract, digestive tract, urinary tract and skin infection caused by sensitive bacteria in cattle, pigs, dogs and cats. There is also a whitlow effect on bovine and sheep mastitis and pig mastitis - hysteritis - agalactia syndrome.

 

Mbofloxacin is a novel fluoroquinolone antibiotic, which inhibits the growth of bacteria by inhibiting THE DNA transcriptase of bacteria, and has antibacterial effects on gram-negative bacteria, gram-positive bacteria and mycoplasma. Mbofloxacin can be well absorbed by oral and injection administration with low toxicity.

Pharmacodynamics: wide antibacterial spectrum and strong antibacterial activity. The MIC90 of most Enterobacter, Pasteurella multocide, Pseudomonas aeruginosa, Staphylococcus aureus and Staphylococcus intermediatus were 0.08-0.28, 0.04, 0.94, 0.2 and 0.23μg/mL, respectively, which were comparable to enrofloxacin and ciprofloxacin. The MIC90 of pasteurella multocide, Pasteurella hemolyticus, Haemophilus comatose and mycoplasma were 0.02, 0.17, 0.03 and 0.48μg/mL, respectively. This product is resistant to the following drugs such as erythromycin, lincomycin, chloramphenicol, doxycycline, sulfonamide drugs of the pathogen is still effective.

 

 

Table 1: Mean pharmacokinetic parameters following intravenous administration of marbofloxacin to 6 adult beagle dogs at a dosage of 2.5 mg/lb.

Parameter

Estimate ± SD* n=6

Total body clearance, (mL/h•kg)

94 ± 8

Volume of distribution at steady state, Vss, (L/kg)

1.19 ± 0.08

AUC0-inf (μg•h/mL)

59 ± 5

Terminal plasma elimination half-life, t1/2(h)

9.5 ± 0.7

* SD = standard deviation

Table 2: Mean pharmacokinetic parameters following oral administration of marbofloxacin tablets to adult beagle dogs at a nominal dosage of 1.25 mg/lb or
2.5 mg/lb and to cats at 2.5 mg/lb.

 

 

Parameters

Dog Estimate ± SD* (1.25 mg/lb) n=6

Dog Estimate ± SD* (2.5 mg/lb) n=6

Cat Estimate ± SD* (2.5 mg/lb) n=7

Time of maximum concentration, Tmax(h)

1.5 ± 0.3

1.8 ± 0.3

1.2 ± 0.6

Maximum concentration, Cmax, (μg/mL)

2.0 ± 0.2

4.2 ± 0.5

4.8 ± 0.7

AUC0-inf (μg•h/mL)

31.2 ± 1.6

64 ± 8

70 ± 6

Terminal plasma elimination half-life, t1/2(h)

10.7 ± 1.6

10.9 ± 0.6

12.7 ± 1.1

mean actual dosages administered to dogs were 1.22 mg/lb and 2.56 mg/lb, respectively, and the mean
actual dosage administered to cats was 2.82 mg/lb.
* SD = standard deviation

Figure 2: Mean plasma concentrations (µg/mL) following single oral administration of marbofloxacin to adult beagle dogs at dosages of 1.25 mg/lb or 2.5 mg/lb.

* See Table 4 in Microbiology section for MIC data.

Figure 2.

Figure 3: Mean plasma concentrations (µg/mL) following single oral administration of marbofloxacin to adult cats at a dosage of 2.5 mg/lb.

* See Table 5 in Microbiology section for MIC data.

Figure 3.

Table 3a: Tissue distribution following a single oral administration of marbofloxacin tablets to adult beagle dogs at a dosage of 1.25 mg/lb*.

Tissue

Marbofloxacin 2 hours (n=4)

Concentrations 18 hours (n=4)

(μg/g ± SD) 24 hours (n=4)

bladder

4.8 ± 1.1

2.6 ± 1.5

1.11 ± 0.19

bone marrow

3.1 ± 0.5

1.5 ± 1.5

0.7 ± 0.2

feces

15 ± 9

48 ± 40

26 ± 11

jejunum

3.6 ± 0.5

1.3 ± 1.0

0.7 ± 0.3

kidney

7.1 ±1.7

1.4 ± 0.5

0.9 ± 0.3

lung

3.0 ± 0.5

0.8 ± 0.2

0.57 ± 0.19

lymph node

5.5 ± 1.1

1.3 ± 0.3

1.0 ± 0.3

muscle

4.1 ± 0.3

1.0 ± 0.3

0.7 ± 0.2

prostate

5.6 ± 1.4

1.8 ± 0.6

1.1 ± 0.4

skin

1.9 ± 0.6

0.41 ± 0.13

0.32 ± 0.08

* SD = standard deviation

Table 3b: Tissue distribution following a single oral administration of marbofloxacin tablets to adult beagle dogs at a dosage of 2.5 mg/lb.

Tissue

Marbofloxacin 2 hours (n=4)

Concentrations 18 hours (n=4)

(μg/g ± SD*) 24 hours (n=4)

bladder

12 ± 4

6 ± 7

1.8 ± 0.4

bone marrow

4.6 ± 1.5

1.28 ± 0.13

0.9 ± 0.3

feces

18 ± 3

52 ± 17

47 ± 28

jejunum

7.8 ± 1.1

2.0 ± 0.3

1.1 ± 0.3

kidney

12.7 ±1.7

2.7 ± 0.3

1.6 ± 0.2

lung

5.48 ± 0.17

1.45 ± 0.19

1.0 ± 0.2

lymph node

8.3 ± 0.7

2.3 ± 0.5

2.03 ± 0.06

muscle

7.5 ± 0.5

1.8 ± 0.3

1.20 ± 0.12

prostate

11 ± 3

2.7 ± 1.0

2.0 ± 0.5

skin

3.20 ± 0.33

0.705 ± 0.013

0.46 ± 0.09

* SD = standard deviation

 

Microbiology

The primary action of fluoroquinolones is to inhibit the bacterial enzyme, DNA gyrase. In susceptible organisms, fluoroquinolones are rapidly bactericidal at relatively low concentrations. Marbofloxacin is bactericidal against a broad range of gram-negative and gram-positive organisms. The minimum inhibitory concentrations (MICs) of pathogens isolated in clinical field studies performed in the United States were determined using National Committee for Clinical Laboratory Standards (NCCLS) standards, and are shown in Tables 4 and 5.

Table 4. MIC Values* (μg/mL) of marbofloxacin against pathogens isolated from skin, soft tissue and urinary tract infections in dogs enrolled in clinical studies conducted during 1994–1996.

Organism

No. of Isolates

MIC50

MIC90

MIC Range

Staphylococcus intermedius

135

0.25

0.25

0.125-2

Escherichia coli

61

0.03

0.06

0.015-2

Proteus mirabilis

35

0.06

0.125

0.03-0.25

Beta-hemolytic Streptococcus,

(not Group A or Group B)

25

1

2

0.5-16

Streptococcus,

Group D enterococcus

16

1

4

0.008-4

Pasteurella multocida

13

0.015

0.06

≤0.008-0.5

Staphylococcus aureus

12

0.25

0.25

0.25-0.5

Enterococcus faecalis

11

2

2

1-4

Klebsiella pneumonia

11

0.06

0.06

0.01-0.06

Pseudomonas spp.

9

**

**

0.06-1

Pseudomonas aeruginosa

7

**

**

0.25-1

* The correlation between in vitro susceptibility data (MIC) and clinical response has not been
determined.
** MIC50 and MIC90 not calculated due to insufficient number of isolates.

Table 5: MIC Values* (μg/mL) of marbofloxacin against pathogens isolated from
skin and soft tissue infections in cats enrolled in clinical studies conducted in 1995
and 1998.

Organism

No. of Isolates

MIC50

MIC90

MIC Range

Pasteurella multocida

135

0.03

0.06

≤0.008-0.25

Beta-hemolytic Streptococcus

22

1

1

0.06-1

Staphylococcus aureus

21

0.25

0.5

0.125-1

Corynebacterium spp.

14

0.5

1

0.25-2

Staphylococcus intermedius

11

0.25

0.5

0.03-0.5

Enterococcus faecalis

10

2.0

2.0

1.0-2.0

Escherichia coli

10

0.03

0.03

0.015-0.03

Bacillus spp.

10

0.25

0.25

0.125-0.25

STORAGE CONDITIONS

Store below 30°C (86°F).

 

HOW SUPPLIED

Zeniquin tablets are available in the following strengths of marbofloxacin and bottle sizes:

25 mg scored tablets supplied in bottles that contain 100 or 250 tablets
50 mg scored tablets supplied in bottles that contain 100 or 250 tablets
100 mg scored tablets supplied in a 50 tablet bottle
200 mg scored tablets supplied in a 50 tablet bottle

Antibacterial Agent Marbofloxacin For Cats Veterinary Drug 115550-35-1 2

Antibacterial Agent Marbofloxacin For Cats Veterinary Drug 115550-35-1 3

 

 

 

 

Get in touch with us

Enter Your Message

You Might Be Into These